To be a world class, anti-fibrotic company developing innovative, targeted therapeutics to treat serious, often life-threatening fibrotic diseases.
Pathological fibrosis is a central driver of organ dysfunction in a wide range of chronic diseases, including systemic sclerosis (SSc) and chronic kidney disease (CKD). Excessive fibrotic activity leads to the progressive accumulation of extracellular matrix, tissue stiffening, and irreversible loss of normal organ architecture and function.
In diseases such as SSc and CKD, fibrosis directly contributes to morbidity, reduced quality of life, and increased mortality. Despite its fundamental role in disease progression, there are currently limited therapies that directly target fibrosis, leaving a significant unmet medical need.
Asengeprast (FT011) is an orally available small molecule being developed to address the underlying drivers of fibrotic disease. Asengeprast has successfully completed a multi-national, phase II clinical trial and has been awarded Orphan Drug Designation by the FDA and EMA for the treatment of scleroderma.
Asengeprast aims to slow fibrotic progression across multiple organs, with the goal of preserving tissue structure and function. Importantly, asengeprast is positioned as a disease-modifying therapy, designed to address the root causes of fibrosis rather than symptom management.
Asengeprast has demonstrated a strong safety and tolerability profile, supported by evaluation across multiple Phase 1 and Phase 2 clinical studies in both healthy participants and patients.
Certa Therapeutics is developing innovative precision therapies for the treatment of fibrotic diseases.
